Thoracic oncology: Annual review;Oncologie thoracique: Revue annuelle

Revue Medicale de Bruxelles

Volumn 34, Issue 2, 2013, Pages 100-111

  Sculier, J P ^a   Berghmans, T ^a   Meert, A P ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Thoracic oncology

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SCREENING; CLINICAL ASSESSMENT; HUMAN; LUNG NODULE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MESOTHELIOMA; SCIENTIFIC LITERATURE; TERMINAL CARE; THORAX CANCER; LUNG TUMOR; REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; SMALL CELL LUNG CARCINOMA;

MLCS; MLOWN;

EID: 84880783801     PISSN: 00353639     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (145)

1. Malvezzi M, Bertuccio P, Levi F, La VC, Negri E: European cancer mortality predictions for the year 2012. Ann Oncol 2012;23:1044-52
2. Moolgavkar SH, Holford TR, Levy DT et al.: Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000. J Natl Cancer Inst 2012;104:541-8
3. Riaz S P, Luchtenborg M, Coupland VH, Spicer J, Peake MD, Moller H: Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer 2012;75:280-4
4. Hoggart C, Brennan P, Tjonneland A et al.: A risk model for lung cancer incidence. Cancer Prev Res (Phila) 2012;5:834-46
5. Smith BM, Pinto L, Ezer N, Sverzellati N, Muro S, Schwartzman K: Emphysema detected on computed tomography and risk of lung cancer: A systematic review and meta-analysis. Lung Cancer 2012;77:58-63
6. Wild P, Gonzalez M, Bourgkard E et al.: Occupational risk factors have to be considered in the definition of high-risk lung cancer populations. Br J Cancer 2012;106:1346-52
7. Brunekreef B, Nnesi-Maesano I, Ayres JG et al.: Ten principles for clean air. Eur Respir J 2012;39:525-8
8. Oken MM, Hocking WG, Kvale PA et al.: Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 2011;306:1865-73
9. Tammemagi CM, Pinsky PF, Caporaso NE et al.: Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. J Natl Cancer Inst 2011;103:1058-68
10. Aberle DR, Adams AM, Berg CD et al.: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409
11. Nawa T, Nakagawa T, Mizoue T et al.: Long-term prognosis of patients with lung cancer detected on low-dose chest computed tomography screening. Lung Cancer 2012;75:197-202
12. Austin JH, Yip R, D'Souza BM, Yankelevitz DF, Henschke CI: Small-cell carcinoma of the lung detected by CT screening: stage distribution and curability. Lung Cancer 2012;76:339-43
13. Ehmann R, Boedeker E, Friedrich U et al.: Canine scent detection in the diagnosis of lung cancer: revisiting a puzzling phenomenon. Eur Respir J 2012;39:669-76
14. Maisonneuve P, Bagnardi V, Bellomi M et al.: Lung Cancer Risk Prediction to Select Smokers for Screening CT: a Model Based on the Italian COSMOS Trial. Cancer Prev Res (Phila) 2011;4:1778-89
15. Wiener RS, Schwartz LM, Woloshin S, Welch HG: Populationbased risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med 2011;155:137-44
16. Steinfort D P, Khor YH, Manser RL, Irving LB: Radial probe endobronchial ultrasound for the diagnosis of peripheral lung cancer: systematic review and meta-analysis. Eur Respir J 2011;37:902-10
17. Ishida T, Asano F, Yamazaki K et al.: Virtual bronchoscopic navigation combined with endobronchial ultrasound to diagnose small peripheral pulmonary lesions: a randomised trial. Thorax 2011;66:1072-7
18. Pecot CV, Li M, Rajanbabu R et al.: Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules. Cancer Epidemiol Biomarkers Prev 2012;21:786-92
19. Fischer BM, Mortensen J, Hansen H et al.: Multimodality approach to mediastinal staging in non-small cell lung cancer. Faults and benefits of PET-CT: a randomised trial. Thorax 2011;66:294-300
20. Darling GE, Maziak DE, Inculet RI et al.: Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial. J Thorac Oncol 2011;6:1367-72
21. Lin M, Ambati C: The management impact of clinically significant incidental lesions detected on staging FDG PET-CT in patients with non-small cell lung cancer (NSCLC): an analysis of 649 cases. Lung Cancer 2012;76:344-9
22. Travis WD, Brambilla E, Noguchi M et al.: International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-85
23. Ellis PM, Blais N, Soulieres D et al.: A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer. J Thorac Oncol 2011;6:1379-91
24. Wallace WA, Rassl DM: Accuracy of cell typing in nonsmall cell lung cancer by EBUS/EUS-FNA cytological samples. Eur Respir J 2011;38:911-7
25. Hetzel J, Eberhardt R, Herth FJ et al.: Cryobiopsy increases the diagnostic yield of endobronchial biopsy: a multicentre trial. Eur Respir J 2012;39:685-90
26. Berghmans T, Pasleau F, Paesmans M et al.: Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations. Eur Respir J 2012;39:9-28
27. Whitson BA, Groth SS, Andrade RS, Maddaus MA, Habermann EB, D'Cunha J: Survival after lobectomy versus segmentectomy for stage I non-small cell lung cancer: a population-based analysis. Ann Thorac Surg 2011;92:1943-50
28. Billmeier SE, Ayanian JZ, Zaslavsky AM, Nerenz DR, Jaklitsch MT, Rogers SO: Predictors and outcomes of limited resection for early-stage non-small cell lung cancer. J Natl Cancer Inst 2011;103:1621-9
29. Wolf AS, Richards WG, Jaklitsch MT et al.: Lobectomy versus sublobar resection for small (2 cm or less) non-small cell lung cancers. Ann Thorac Surg 2011;92:1819-23
30. Donahue JM, Morse CR, Wigle DA et al.: Oncologic efficacy of anatomic segmentectomy in stage IA lung cancer patients with T1a tumors. Ann Thorac Surg 2012;93:381-7
31. Scagliotti GV, Pastorino U, Vansteenkiste JF et al.: Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non-Small-Cell Lung Cancer. J Clin Oncol 2012;30:172-8
32. Kim AW, Boffa DJ, Wang Z, Detterbeck FC: An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non-small cell lung cancer. J Thorac Cardiovasc Surg 2012;143:55-63
33. Booth CM, Shepherd FA, Peng Y et al.: Adjuvant chemotherapy for non-small cell lung cancer: practice patterns and outcomes in the general population of Ontario, Canada. J Thorac Oncol 2012;7:559-66
34. Von Meyenfeldt EM, Gooiker GA, Van Gijn W et al.: The relationship between volume or surgeon specialty and outcome in the surgical treatment of lung cancer: a systematic review and meta-analysis. J Thorac Oncol 2012;7:1170-8
35. Matsuo Y, Shibuya K, Nagata Y et al.: Preliminary Report of Late Recurrences, at 5 Years or More, after Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer. J Thorac Oncol 2012;7:453-6
36. Takeda A, Kunieda E, Sanuki N, Aoki Y, Oku Y, Handa H: Stereotactic body radiotherapy (SBRT) for solitary pulmonary nodules clinically diagnosed as lung cancer with no pathological confirmation: Comparison with non-small-cell lung cancer. Lung Cancer 2012;77:77-82
37. Boni C, Tiseo M, Boni L et al.: Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV nonsmall cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). Br J Cancer 2012;106:658-65
38. Jungels C, Berghmans T, Meert A P, Lafitte JJ, Scherpereel A, Sculier JP: Traitement de rattrapage par pémétrexed pour les CBNPC: étude rétrospective d'implémentation. Rev Mal Respir 2012;29:21-7
39. Paz-Ares L, De MF, Dediu M et al.: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012;13:247-55
40. Zhang X, Zang J, Xu J et al.: Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: a systematic review and meta-analysis. Chest 2011;140:117-26
41. Vilmar AC, Sorensen JB. Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives. Eur Respir Rev 2011;20:45-52
42. Yin M, Yan J, Voutsina A et al.: No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer 2011;72:370-7
43. Wu J, Liu J, Zhou Y et al.: Predictive Value of XRCC1 Gene Polymorphisms on Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer Patients: A Systematic Review and Meta-analysis. Clin Cancer Res 2012;18:3972-81
44. Wang LE, Yin M, Dong Q et al.: DNA repair capacity in peripheral lymphocytes predicts survival of patients with nonsmall-cell lung cancer treated with first-line platinum-based chemotherapy. J Clin Oncol 2011;29:4121-8
45. Gong W, Zhang X, Wu J et al.: RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Lung Cancer 2012;75:374-80
46. Zhang HL, Ruan L, Zheng LM, Whyte D, Tzeng CM, Zhou XW: Association between class III beta-tubulin expression and response to paclitaxel/vinorebine- based chemotherapy for nonsmall cell lung cancer: A meta-analysis. Lung Cancer 2012;77:9-15
47. Reiman T, Lai R, Veillard AS et al.: Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol 2012;23:86-93
48. Camidge DR, Kono SA, Lu X et al.: Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 2011;6:774-80
49. Lee JO, Kim TM, Lee SH et al.: Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol 2011;6:1474-80
50. Sun JM, Han J, Ahn JS, Park K, Ahn MJ: Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol 2011;6:1392-9
51. Brahmer JR, Tykodi SS, Chow LQ et al.: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65
52. Topalian SL, Hodi FS, Brahmer JR et al.: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54
53. Fukuoka M, Wu YL, Thongprasert S et al.: Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-74
54. Rosell R, Carcereny E, Gervais R et al.: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46
55. Zhou C, Wu YL, Chen G et al.: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802):a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42
56. Han JY, Park K, Kim SW et al.: First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung. J Clin Oncol 2012;30:1122-8
57. Gaafar RM, Surmont V F, Scagliotti GV et al.: A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). Eur J Cancer 2011;47:2331-40
58. Scagliotti GV, Krzakowski M, Szczesna A et al.: Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial. J Clin Oncol 2012;30:2070-8
59. Lee JS, Hirsh V, Park K et al.: Vandetanib Versus Placebo in Patients With Advanced Non-Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR). J Clin Oncol 2012;30:1114-21
60. Natale RB, Thongprasert S, Greco FA et al.: Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2011;29:1059-66
61. Tseng JS, Yang TY, Chen KC, Hsu KH, Chen HY, Chang GC: Retrospective study of erlotinib in patients with advanced squamous lung cancer. Lung Cancer 2012;77:128-33
62. Oxnard GR, Janjigian Y Y, Arcila ME et al.: Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib. Clin Cancer Res 2011;17:6322-8
63. Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ: Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design. Clin Cancer Res 2011;17:6298-303
64. Girard N, Sima CS, Jackman DM et al.: Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J 2012;39:366-72
65. Brugger W, Triller N, Blasinska-Morawiec M et al.: Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2011;29:4113-20
66. D'Angelo S P, Pietanza MC, Johnson ML et al.: Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas. J Clin Oncol 2011;29:2066-70
67. Su KY, Chen HY, Li KC et al.: Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol 2012;30:433-40
68. Zhou Q, Zhang XC, Chen ZH et al.: Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2011;29:3316-21
69. Lee Y, Shim HS, Park MS et al.: High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma. Clin Cancer Res 2012;18:1760-8
70. Takahashi R, Hirata H, Tachibana I et al.: Early [18F]Fluorodeoxyglucose Positron Emission Tomography at Two Days of Gefitinib Treatment Predicts Clinical Outcome in Patients with Adenocarcinoma of the Lung. Clin Cancer Res 2012;18:220-8
71. Leary A F, Castro DG, Nicholson AG et al.: Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors. Eur J Cancer 2012;48:61-7
72. Yatabe Y, Matsuo K, Mitsudomi T: Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma. J Clin Oncol 2011;29:2972-7
73. Mascaux C, Wynes MW, Kato Y et al.: EGFR Protein Expression in Non-Small Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitor: A Novel Antibody for Immunohistochemistry or AQUA Technology. Clin Cancer Res 2011;17:7796-807
74. Brevet M, Johnson ML, Azzoli CG, Ladanyi M: Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 2011;73:96-102
75. Yam I, Lam DC, Chan K et al.: EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non-Small Cell Lung Cancer Patients. J Thorac Oncol 2012;7:1131-40
76. Taniguchi K, Uchida J, Nishino K et al.: Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas. Clin Cancer Res 2011;17:7808-15
77. Paik JH, Choi CM, Kim H et al.: Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 2012;76:403-9
78. Doebele RC, Pilling AB, Aisner DL et al.: Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer. Clin Cancer Res 2012;18:1472-82
79. Bergethon K, Shaw AT, Ignatius Ou SH et al.: ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers. J Clin Oncol 2012;30:863-70
80. Paik PK, Arcila ME, Fara M et al.: Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations. J Clin Oncol 2011;29:2046-51
81. Raz DJ, Lanuti M, Gaissert HC, Wright CD, Mathisen DJ, Wain JC: Outcomes of patients with isolated adrenal metastasis from non-small cell lung carcinoma. Ann Thorac Surg 2011;92:1788-92
82. Salah S, Tanvetyanon T, Abbasi S: Metastatectomy for extracranial extra-adrenal non-small cell lung cancer solitary metastases: systematic review and analysis of reported cases. Lung Cancer 2012;75:9-14
83. Rivera C, Falcoz PE, Bernard A, Thomas PA, Dahan M: Surgical management and outcomes of elderly patients with early stage non-small cell lung cancer: a nested case-control study. Chest 2011;140:874-80
84. Rivera C, Dahan M, Bernard A, Falcoz PE, Thomas P: Surgical treatment of lung cancer in the octogenarians: results of a nationwide audit. Eur J Cardiothorac Surg 2011;39:981-6
85. Rivera M P, Detterbeck FC, Socinski MA et al.: Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer. Chest 2009;135:1588-95
86. Wanders R, Steevens J, Botterweck A et al.: Treatment with curative intent of stage III non-small cell lung cancer patients of 75 years: a prospective population-based study. Eur J Cancer 2011;47:2691-7
87. Davidoff AJ, Gardner J F, Seal B, Edelman MJ: Populationbased estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced nonsmall cell lung cancer. J Thorac Oncol 2011;6:934-41
88. Quoix E, Zalcman G, Oster JP et al.: Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011;378:1079-88
89. Rossi A, Di MM, Chiodini P et al.: Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data. J Clin Oncol 2012;30:1692-8
90. Schmittel A, Sebastian M, Fischer Von WL et al.: A German multicenter, randomized phase III trial comparing irinotecancarboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol 2011;22:1798-804
91. Shao N, Jin S, Zhu W: An updated meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2012;7:470-2
92. Owonikoko TK, Behera M, Chen Z et al.: A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol 2012;7:866-72
93. Janssen-Heijnen ML, Maas HA, Siesling S, Koning CC, Coebergh JW, Groen HJ: Treatment and survival of patients with small-cell lung cancer: small steps forward, but not for patients > 80. Ann Oncol 2012;23:954-60
94. Janssen-Heijnen ML, Maas HA, Van De Schans SA, Coebergh JW, Groen HJ: Chemotherapy in elderly small-cell lung cancer patients: yes we can, but should we do it? Ann Oncol 2011;22:821-6
95. Knez L, Sodja E, Kern I, Kosnik M, Cufer T: Predictive value of multidrug resistance proteins, topoisomerases II and ERCC1 in small cell lung cancer: a systematic review. Lung Cancer 2011;72:271-9
96. Kadara H, Behrens C, Yuan P et al.: A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res 2011;17:1490-501
97. Mitra R, Lee J, Jo J et al.: Prediction of Postoperative Recurrence-Free Survival in Non-Small Cell Lung Cancer by Using an Internationally Validated Gene Expression Model. Clin Cancer Res 2011;17:2934-46
98. Chen DT, Hsu YL, Fulp WJ et al.: Prognostic and predictive value of a malignancy-risk gene signature in early-stage nonsmall cell lung cancer. J Natl Cancer Inst 2011;103:1859-70
99. De Fraipont F, Levallet G, Creveuil C et al.: An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial. Clin Cancer Res 2012;18:2976-86
100. Rotunno M, Hu N, Su H et al.: A gene expression signature from peripheral whole blood for stage I lung adenocarcinoma. Cancer Prev Res (Phila) 2011;4:1599-608
101. Silva J, Garcia V, Zaballos A et al.: Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. Eur Respir J 2011;37:617-23
102. Jordan B: Des signatures sans valeur? Med Sci (Paris) 2012;28:547-50
103. Grivaux M, Zureik M, Marsal L et al.: Five-year survival for lung cancer patients managed in general hospitals. Rev Mal Respir 2011;28:e31-8
104. Sawabata N, Miyaoka E, Asamura H et al.: Japanese lung cancer registry study of 11, 663 surgical cases in 2004: demographic and prognosis changes over decade. J Thorac Oncol 2011;6:1229-35
105. Maeda R, Ishii G, Yoshida J, Hishida T, Nishimura M, Nagai K: Influence of cigarette smoking on histological subtypes of stage I lung adenocarcinoma. J Thorac Oncol 2011;6:743-50
106. Shimada Y, Yoshida J, Hishida T, Nishimura M, Ishii G, Nagai K: Predictive Factors of Pathologically Proven Noninvasive Tumor Characteristics in T1aN0M0 Peripheral Non-small Cell Lung Cancer. Chest 2012;141:1003-9
107. Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K: Poor prognostic factors in patients with stage IB non-small cell lung cancer according to the seventh edition TNM classification. Chest 2011;139:855-61
108. Saji H, Tsuboi M, Yoshida K et al.: Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer. J Thorac Oncol 2011;6:1865-71
109. Rusch VW, Hawes D, Decker PA et al.: Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol 2011;29:4313-9
110. Jonnalagadda S, Smith C, Mhango G, Wisnivesky JP: The Number of Lymph Node Metastases as a Prognostic Factor in Patients With N1 Non-small Cell Lung Cancer. Chest 2011;140:433-40
111. Sagerup CM, Smastuen M, Johannesen TB, Helland A, Brustugun OT: Sex-specific trends in lung cancer incidence and survival: a population study of 40, 118 cases. Thorax 2011;66:301-7
112. Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K: The prognostic impact of cigarette smoking on patients with non-small cell lung cancer. J Thorac Oncol 2011;6:735-42
113. Jones LW, Hornsby WE, Goetzinger A et al.: Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer. Lung Cancer 2012;76:248-52
114. Di Maio M., Signoriello S, Morabito A et al.: Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials. Lung Cancer 2012;76:457-64
115. Sloan JA, Zhao X, Novotny PJ et al.: Relationship between deficits in overall quality of life and non-small-cell lung cancer survival. J Clin Oncol 2012;30:1498-504
116. Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA: Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011;6:1496-504
117. Paesmans M, Lafitte JJ, Lecomte J et al.: Validation and comparison of several published prognostic systems for patients with small cell lung cancer. Eur Respir J 2011;38:657-63
118. Sirera R, Bremnes RM, Cabrera A et al.: Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011;6:286-90
119. Hou JM, Krebs MG, Lancashire L et al.: Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012;30:525-32
120. Krebs MG, Sloane R, Priest L et al.: Evaluation and prognostic significance of circulating tumor cells in patients with non-smallcell lung cancer. J Clin Oncol 2011;29:1556-63
121. Marchetti A, Felicioni L, Malatesta S et al.: Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011;29:3574-9
122. Edelman MJ, Hodgson L, Rosenblatt PY et al.: CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. J Thorac Oncol 2012;7:649-54
123. Tong J, Sun X, Cheng H et al.: Expression of p16 in non-small cell lung cancer and its prognostic significance: a meta-analysis of published literatures. Lung Cancer 2011;74:155-63
124. Pajares MJ, Agorreta J, Larrayoz M et al.: Expression of tumorderived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol 2012;30:1129-36
125. Lopez-Encuentra A, Lopez-Rios F, Conde E et al.: Composite anatomical-clinical-molecular prognostic model in non-small cell lung cancer. Eur Respir J 2011;37:136-42
126. Temel JS, Greer JA, Admane S et al.: Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. J Clin Oncol 2011;29:2319-26
127. Greer JA, Pirl W F, Jackson VA et al.: Effect of Early Palliative Care on Chemotherapy Use and End-of-Life Care in Patients With Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol 2012;30:394-400
128. Meeussen K, Van Den BL, Echteld MA et al.: End-of-Life Care and Circumstances of Death in Patients Dying As a Result of Cancer in Belgium and the Netherlands: A Retrospective Comparative Study. J Clin Oncol 2011;29:4327-34
129. Fang F, Fall K, Mittleman MA et al.: Suicide and cardiovascular death after a cancer diagnosis. N Engl J Med 2012;366:1310-8
130. Schmidt-Hansen M, Baldwin DR, Hasler E: What is the Most Effective Follow-up Model for Lung Cancer Patients? A Systematic Review. J Thorac Oncol 2012;7:821-4
131. Choi SH, Kim YT, Kim SK et al.: Positron emission tomographycomputed tomography for postoperative surveillance in nonsmall cell lung cancer. Ann Thorac Surg 2011;92:1826-32
132. Janssen-Heijnen ML, Van Steenbergen LN, Steyerberg E, Visser O, De Ruysscher DK, Groen HJ:: Long-Term Excess Mortality for Survivors of Non-small Cell Lung Cancer in the Netherlands. J Thorac Oncol 2012;7:496-502
133. Boxer MM, Vinod SK, Shafiq J, Duggan KJ: Do multidisciplinary team meetings make a difference in the management of lung cancer? Cancer 2011;117:5112-20
134. Osarogiagbon RU, Phelps G, McFarlane J, Bankole O: Causes and consequences of deviation from multidisciplinary care in thoracic oncology. J Thorac Oncol 2011;6:510-6
135. Salloum RG, Smith TJ, Jensen GA, Lafata JE: Factors associated with adherence to chemotherapy guidelines in patients with non-small cell lung cancer. Lung Cancer 2012;75:255-60
136. Rich AL, Tata LJ, Stanley RA et al.: Lung cancer in England: Information from the National Lung Cancer Audit (LUCADA). Lung Cancer 2011;72:16-22
137. Van Der Drift MA, Karim-Kos HE, Siesling S et al.: Progress in Standard of Care Therapy and Modest Survival Benefits in the Treatment of Non-small Cell Lung Cancer Patients in the Netherlands in the Last 20 Years. J Thorac Oncol 2012;7:291-8
138. Riaz S P, Luchtenborg M, Jack RH et al.: Variation in surgical resection for lung cancer in relation to survival: populationbased study in England 2004-2006. Eur J Cancer 2012;48:54-60
139. Rich AL, Tata LJ, Free CM et al.: How do patient and hospital features influence outcomes in small-cell lung cancer in England? Br J Cancer 2011;105:746-52
140. Freixinet JL, Varela G, Molins L et al.: Benchmarking in thoracic surgery. Eur J Cardiothorac Surg 2011;40:124-9
141. Treasure T, Lang-Lazdunski L, Waller D et al.: Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011;12:763-72
142. Damhuis RA, Schroten C, Burgers JA: Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Eur Respir J 2012;40:185-9
143. Musk AW, Olsen N, Alfonso H et al.: Predicting survival in malignant mesothelioma. Eur Respir J 2011;38:1420-4
144. Scherpereel A, Berghmans T, Lafitte JJ et al.: Valproatedoxorubicin: promising therapy for progressing mesothelioma. A phase II study. Eur Respir J 2011;37:129-35
145. Hollevoet K, Reitsma JB, Creaney J et al.: Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012;30:1541-9